Опубликована: Янв. 1, 2024
Язык: Английский
Medicina, Год журнала: 2024, Номер 60(1), С. 115 - 115
Опубликована: Янв. 7, 2024
Neuropsychiatric symptoms (NPS), including depression, anxiety, apathy, visual hallucinations, and impulse control disorders, are very common during the course of Parkinson’s disease (PD), occurring even at prodromal premotor stages. Mild behavioral impairment (MBI) represents a recently described neurobehavioral syndrome, characterized by emergence persistent impactful NPS in later life, reflecting arisk dementia. Accumulating evidence suggests that MBI is highly prevalent non-demented patients with PD, also being associated an advanced stage, more severe motor deficits, as well global multiple-domain cognitive impairment. Neuroimaging studies have revealed PD may be related todistinct patterns brain atrophy, altered neuronal connectivity, distribution dopamine transporter (DAT) depletion, shedding light on its pathophysiological background. Genetic shown specific single-nucleotide polymorphisms (SNPs) MBI, paving way for future research this field. In review, we summarize critically discuss emerging frequency, clinical genetic factors, neuroanatomical neurophysiological correlates aiming to elucidate underlying pathophysiology potential role early “marker” decline, particularly population. addition, aim identify gaps, propose novel relative areas interest could aid our better understanding relationship newly defined diagnostic entity PD.
Язык: Английский
Процитировано
7
Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery), Год журнала: 2024, Номер 8, С. 982 - 991
Опубликована: Авг. 17, 2024
Parkinson's disease is a progressive neurodegenerative with motor symptoms and non-motor impairments, including depression, observed in 2.7-90% of cases. Depression frequently underestimated diagnosed late due to its similarity disease, such as fatigue, sleep disturbances, hypomimia, etc. In approximately 25% patients, depression precedes symptoms, which may indicate connection the pathogenesis disease. The purpose study was analyze current data on pathophysiology, diagnosis, treatment patients results have demonstrated that pathophysiological mechanisms include neurodegeneration dopaminergic, noradrenergic, serotonergic neurons, neuroinflammation, impaired neuroplasticity. For timely treatment, especially those changes or should be regularly examined. Treatment based multimodal approach includes use supportive psychotherapy pharmacotherapy. Alternative methods exercise, cognitive behavioral therapy, transcranial magnetic stimulation, electroconvulsive therapy are also being explored. Thus, requires an individualized approach. Further research into this problem crucial develop improve patient management algorithms.
Язык: Английский
Процитировано
6
Cells, Год журнала: 2024, Номер 13(15), С. 1301 - 1301
Опубликована: Авг. 4, 2024
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that lacks effective treatment strategies to halt or delay its progression. The homeostasis of Ca2+ ions crucial for ensuring optimal cellular functions and survival, especially neuronal cells. In the context PD, systems regulating are compromised, leading Ca2+-dependent synaptic dysfunction, impaired plasticity, ultimately, loss. Recent research efforts directed toward understanding pathology PD have yielded significant insights, particularly highlighting close relationship between dysregulation, neuroinflammation, neurodegeneration. However, precise mechanisms driving selective loss dopaminergic neurons in remain elusive. disruption key factor, engaging various neuroinflammatory pathways affecting intracellular organelles store Ca2+. Specifically, functioning mitochondria, lysosomes, endoplasmic reticulum (ER) metabolism believed contribute disease’s pathophysiology. Na+-Ca2+ exchanger (NCX) considered an important regulator cell types, including neurons, astrocytes, microglia. Alterations NCX activity associated with processes different models PD. this review, we will explore role dysregulation neuroinflammation as primary drivers PD-related neurodegeneration, emphasis on pivotal Consequently, NCXs their interplay may emerge potentially players underlying providing promising avenue therapeutic intervention aimed at halting
Язык: Английский
Процитировано
4
Journal of Neurology, Год журнала: 2025, Номер 272(2)
Опубликована: Янв. 15, 2025
Язык: Английский
Процитировано
0
Journal of Psychiatric Research, Год журнала: 2025, Номер 184, С. 48 - 55
Опубликована: Фев. 25, 2025
Язык: Английский
Процитировано
0
Mental health and physical activity, Год журнала: 2025, Номер unknown, С. 100677 - 100677
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
International Clinical Psychopharmacology, Год журнала: 2025, Номер unknown
Опубликована: Март 12, 2025
Depression is a common comorbidity in Parkinson’s disease (PD), significantly reducing patients’ quality of life. This mini-review examines pharmacological and nonpharmacological therapies for managing depression PD, analyzing their benefits, limitations. Pharmacological options include tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), norepinephrine (SNRIs), levodopa, dopaminergic agonists, monoamine oxidase B inhibitors. Nonpharmacological strategies involve brief psychodynamic therapy, cognitive-behavioral therapy (CBT), physical exercise, phytomedicine, massage music phototherapy, yoga, repetitive transcranial magnetic stimulation (rTMS), direct current stimulation, electroconvulsive (ECT), deep brain stimulation. SSRIs, SNRIs, some dopamine agonists have shown effectiveness good tolerability, especially when combined with CBT or rTMS. For severe refractory cases, ECT remains viable option. Although many these show promise, the limited number scale studies each treatment restrict strength evidence. Further large-scale, multicenter randomized-controlled trials are essential to validate preliminary findings establish evidence-based guidelines. In addition, potential benefits social support context PD-related require further exploration provide holistic care this population.
Язык: Английский
Процитировано
0
Journal of Parkinson s Disease, Год журнала: 2025, Номер unknown
Опубликована: Апрель 3, 2025
Background The patient experience of Parkinson's disease (PD) is heterogeneous, with limited prognostic tools to predict individual outcomes, leading significant uncertainty for people PD. Under-recognition both psychosocial and biological drivers fear in by clinicians may further contribute distress. Objective objective the present study investigate Methods In-depth interviews were conducted twenty PD (11 semi-structured, 9 guided/prompted). Thematic analysis organized fears/uncertainties topic as well contextual factors such timing (e.g., active or anticipatory; at time diagnosis developed subsequent diagnosis) lexicon used describe it. Results Participants expressed a wide range fears uncertainties about their future quality life PD, which shifted progression. Most anticipatory rather than response current concerns. reported substantial influence from media personalities family/friends participants that they had not disclosed healthcare providers. Conclusions Clinicians caring should be aware often-unspoken uncertainties, carry burden. Open acknowledgement normalization help patients feel less isolated disease.
Язык: Английский
Процитировано
0
European Journal of Pharmacology, Год журнала: 2025, Номер unknown, С. 177602 - 177602
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0
Journal of dementia and Alzheimer's disease, Год журнала: 2024, Номер 1(1), С. 3 - 21
Опубликована: Июнь 22, 2024
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms due to the loss of dopamine-producing neurons presence Lewy bodies in brain. While current treatments such as dopamine replacement with levodopa deep brain stimulation mainly manage do not stop progression, recent advancements nanomedicine provide promising new therapy options. These include drug-loaded nanocarriers that improve drug delivery brain, enhancing effectiveness reducing side effects. This review explores novel nanomedical approaches like solid lipid (SLNs), which could profiles decrease adverse effects seen traditional PD treatments. Additionally, it discusses challenge crossing blood–brain barrier, crucial for treating central nervous system disorders, how facilitate targeted delivery. Despite these advancements, emphasizes more research into safety long-term impacts PD, highlighting moving from lab clinical use.
Язык: Английский
Процитировано
2